Wednesday, November 19, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Analyst Concerns Mount for Hims & Hers Growth Trajectory

Robert Sasse by Robert Sasse
August 20, 2025
in Stocks
0
Hims & Hers Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

The once-bright growth narrative for telehealth provider Hims & Hers is showing significant cracks. Market experts are now raising fundamental questions about the company’s future momentum, casting doubt on whether the stock can sustain its previous rally in the face of growing headwinds.

Significant Price Target Reduction Sparks Concern

In a notable shift in sentiment, Truist Securities has executed a substantial reduction in its price target for Hims & Hers. The investment bank slashed its target to $37 from $48, a move that signals deepening skepticism regarding the company’s prospects. While Truist maintained its “Hold” rating for the time being, the drastic cut clearly indicates that confidence in the established growth story is eroding.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Core Growth Drivers Under Scrutiny

This pessimistic reassessment is rooted in specific and concrete worries over future revenue, with a particular focus on projections for 2026. Analysts highlighted a disappointing revenue outlook and assessed expectations for GLP-1-related sales in the latter half of the year as merely “moderate.” Furthermore, Truist analysts suggested that the recent acquisition of Zava will likely only be sufficient to help the company meet the lower end of its forecasts. They concluded that the deal does little to alleviate the more profound, fundamental concerns about long-term growth sustainability.

A Convergence of Negative Pressures

These analyst doubts have manifested in tangible market performance. The company’s shares declined approximately eight percent in a single week. This recent weakness compounds existing pressure on the stock, which is already navigating a tense market environment further burdened by substantial insider selling activity and the looming threat of class-action lawsuits. The question for investors is whether Hims & Hers can successfully counter this wave of skepticism or if the analysts’ gloomy forecast will prove accurate.

Ad

Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from November 19 delivers the answer:

The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 19.

Hims & Hers: Buy or sell? Read more here...

Tags: Hims & Hers
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Inspire Medical Stock

Institutional Confidence Grows for Inspire Medical Amid Mixed Analyst Sentiment

Appian Stock

Appian Unveils Strategic AI Platform Enhancements for Enterprise Automation

Unitedhealth Stock

UnitedHealth Investment by Berkshire Sparks Initial Rally, But Concerns Linger

Recommended

Pickleball sports

Anticipated Earnings Report for Manchester United Analyzing Past Performance and Future Expectations

2 years ago
IT-Healthcare

UnitedHealth Groups Resilient 2023 Performance A Look at Key Highlights

2 years ago
Neurotech

Understanding Trading Halts and Resumptions

2 years ago
Chefs' Warehouse Stock

A Specialty Distributor Defies Industry Headwinds with Strong Quarterly Performance

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Palantir’s European Expansion Gains Momentum Through Strategic Alliance

Ethereum’s Contrarian Moment: Whales Accumulate Amid Widespread Fear

D-Wave Quantum Faces Critical Warrant Deadline Amid Strong Financial Performance

Institutional Investors Show Divided Stance on UPS Shares

Uranium Energy Secures Major Funding for US Production Expansion

Amazon Shares Face Pressure as Analyst Downgrade Raises AI Investment Concerns

Trending

Workiva Stock
Earnings

Workiva Shares Maintain Impressive Growth Trajectory

by Dieter Jaworski
November 19, 2025
0

Workiva continues to demonstrate remarkable momentum in equity markets, with its stock advancing more than 18% over...

XRP Stock

XRP Faces Critical Test as ETF Momentum Fails to Lift Prices

November 19, 2025
3M Stock

Market Experts Rally Behind 3M’s Resurgent Performance

November 19, 2025
Palantir Stock

Palantir’s European Expansion Gains Momentum Through Strategic Alliance

November 19, 2025
Ethereum Stock

Ethereum’s Contrarian Moment: Whales Accumulate Amid Widespread Fear

November 19, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Workiva Shares Maintain Impressive Growth Trajectory
  • XRP Faces Critical Test as ETF Momentum Fails to Lift Prices
  • Market Experts Rally Behind 3M’s Resurgent Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com